Literature DB >> 32131058

Laser-assisted 3D bioprinting of exocrine pancreas spheroid models for cancer initiation study.

Davit Hakobyan1, Chantal Médina, Nathalie Dusserre, Marie-Laure Stachowicz, Charles Handschin, Jean-Christophe Fricain, Julie Guillermet-Guibert, Hugo Oliveira.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas. It has shown a poor prognosis and a rising incidence in the developed world. Other pathologies associated with this tissue include pancreatitis, a risk condition for pancreatic cancer. The onset of both pancreatitis and pancreatic cancer follows a common pattern: exocrine pancreatic acinar cells undergo a transdifferentiation to duct cells that triggers a 3D restructuration of the pancreatic tissue. However, the exact mechanism underlying this process remains partially undefined. Further understanding the cellular events leading to PDAC could open new avenues in the development of novel therapeutic approaches. Since current 2D cell culture models fail to mimic the tridimensional complexity of the pancreatic tissue, new in vitro models are urgently needed. Here, we generated 3D pancreatic cell spheroid arrays using laser-assisted bioprinting and characterized their phenotypic evolution over time through image analysis and phenotypic characterization. We show that these bioprinted spheroids, composed of both acinar and ductal cells, can replicate the initial stages of PDAC development. This bioprinted miniaturized spheroid-based array model should prove useful for the study of the internal and external factors that contribute to the formation of precursor PDAC lesions and to cancer progression, and may therefore shed light on future PDAC therapy strategies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32131058     DOI: 10.1088/1758-5090/ab7cb8

Source DB:  PubMed          Journal:  Biofabrication        ISSN: 1758-5082            Impact factor:   9.954


  9 in total

Review 1.  Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion.

Authors:  Rafał Staros; Agata Michalak; Kinga Rusinek; Krzysztof Mucha; Zygmunt Pojda; Radosław Zagożdżon
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

2.  In situ 3D bioprinting with bioconcrete bioink.

Authors:  Mingjun Xie; Yang Shi; Chun Zhang; Mingjie Ge; Jingbo Zhang; Zichen Chen; Jianzhong Fu; Zhijian Xie; Yong He
Journal:  Nat Commun       Date:  2022-06-23       Impact factor: 17.694

Review 3.  Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives.

Authors:  Awaji Y Safhi
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

Review 4.  Organoid technology for personalized pancreatic cancer therapy.

Authors:  Axel Bengtsson; Roland Andersson; Jonas Rahm; Karthik Ganganna; Bodil Andersson; Daniel Ansari
Journal:  Cell Oncol (Dordr)       Date:  2021-01-25       Impact factor: 6.730

Review 5.  Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.

Authors:  Marlene Geyer; Karla Queiroz
Journal:  Front Cell Dev Biol       Date:  2021-12-23

Review 6.  Using Spheroids as Building Blocks Towards 3D Bioprinting of Tumor Microenvironment.

Authors:  Pei Zhuang; Yi-Hua Chiang; Maria Serafim Fernanda; Mei He
Journal:  Int J Bioprint       Date:  2021-10-21

Review 7.  3D bioprinting of complex tissues in vitro: state-of-the-art and future perspectives.

Authors:  Yi Xiang; Kathleen Miller; Jiaao Guan; Wisarut Kiratitanaporn; Min Tang; Shaochen Chen
Journal:  Arch Toxicol       Date:  2022-01-10       Impact factor: 5.153

Review 8.  An Organotypic Microcosm for the Pancreatic Tumor Microenvironment.

Authors:  Miranda Lin; Mei Gao; Prakash K Pandalai; Michael J Cavnar; Joseph Kim
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

Review 9.  3D-Printed Immunosensor Arrays for Cancer Diagnostics.

Authors:  Mohamed Sharafeldin; Karteek Kadimisetty; Ketki S Bhalerao; Tianqi Chen; James F Rusling
Journal:  Sensors (Basel)       Date:  2020-08-12       Impact factor: 3.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.